KR62436

**KR62436** is an experimental **small-molecule dipeptidyl peptidase-4 inhibitor** developed in preclinical research as an antidiabetic agent. By inhibiting DPP-4, it prevents enzymatic degradation of endogenous incretins such as GLP-1, supporting glucose-lowering activity in vivo. Published preclinical studies describe KR62436 as a potent and selective DPP-4 inhibitor, but there is no clear evidence that it advanced to marketed status; it has also been used extensively as a research tool in cancer biology studies, where DPP-4 inhibition with KR62436 promoted autophagy, epithelial-mesenchymal transition, tumor growth, and metastasis in breast cancer models.

Other names

6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile